Repurposing a platelet aggregation inhibitor ticagrelor as an antimicrobial against Clostridioides difficile
Open Access
- 16 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 10 (1), 1-8
- https://doi.org/10.1038/s41598-020-63199-x
Abstract
Drug resistance in Clostridioides difficile becomes a public health concern worldwide, especially as the hypervirulent strains show decreased susceptibility to the first-line antibiotics for C. difficile treatment. Therefore, the simultaneous discovery and development of new compounds to fight this pathogen are urgently needed. In order to determinate new drugs active against C. difficile, we identified ticagrelor, utilized for the prevention of thrombotic events, as exhibiting potent growth-inhibitory activity against C. difficile. Whole-cell growth inhibition assays were performed and compared to vancomycin and metronidazole, followed by determining time-kill kinetics against C. difficile. Activities against biofilm formation and spore germination were also evaluated. Leakage analyses and electron microscopy were applied to confirm the disruption of membrane structure. Finally, ticagrelor’s ability to synergize with vancomycin and metronidazole was determined using checkerboard assays. Our data showed that ticagrelor exerted activity with a MIC range of 20–40 µg/mL against C. difficile. This compound also exhibited an inhibitory effect on biofilm formation and spore germination. Additionally, ticagrelor did not interact with vancomycin nor metronidazole. Our findings revealed for the first time that ticagrelor could be further developed as a new antimicrobial agent for fighting against C. difficile.This publication has 33 references indexed in Scilit:
- Antibacterial Activity of Ticagrelor in Conventional Antiplatelet Dosages Against Antibiotic-Resistant Gram-Positive BacteriaJAMA Cardiology, 2019
- Clostridium difficile infection: reviewEuropean Journal of Clinical Microbiology & Infectious Diseases, 2019
- Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infectionsAnnals of the New York Academy of Sciences, 2018
- Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)Clinical Infectious Diseases, 2018
- Insights into drug resistance mechanisms in Clostridium difficileEssays in Biochemistry, 2017
- Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O’Toole 1935) Prévot 1938Anaerobe, 2016
- Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparisonJournal of Antimicrobial Chemotherapy, 2014
- Defining Fractional Inhibitory Concentration Index Cutoffs for Additive Interactions Based on Self-Drug Additive Combinations, Monte Carlo Simulation Analysis, and In Vitro - In Vivo Correlation Data for Antifungal Drug Combinations against Aspergillus fumigatusAntimicrobial Agents and Chemotherapy, 2010
- Microarray Identification of Clostridium difficile Core Components and Divergent Regions Associated with Host OriginJournal of Bacteriology, 2009
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004